Table 1.
Demographics and clinical characteristics of patients with MS who presented with side effects following vaccination against SARS-CoV-2.
| N | (%) | Mean | Median | IQR | SD | |
|---|---|---|---|---|---|---|
| Study population | 1,668 | 100 | ||||
| Sex | ||||||
| Female | 1,209 | 72.48 | ||||
| Male | 459 | 27.52 | ||||
| Whole study population age | 41.88 | 42 | 16 | 11.07 | ||
| Female age | 42.03 | 42 | 16 | 11.21 | ||
| Male age | 41.49 | 41 | 16 | 10.68 | ||
| Disease course | ||||||
| RRMS | 1,585 | 95.02 | ||||
| SPMS | 42 | 2.52 | ||||
| PPMS | 41 | 2.46 | ||||
| EDSS | 2.36 | 2 | 2.5 | 1.48 | ||
| ≤2 | 917 | 54.98 | ||||
| 3–4 | 658 | 39.44 | ||||
| ≥5 | 93 | 5.58 | ||||
| Disease duration | 9.44 | 8 | 9 | 6.34 | ||
| DMTs | ||||||
| Interferon beta | 377 | 22.6 | ||||
| Glatiramer acetate | 134 | 8.03 | ||||
| Dimethyl fumarate | 665 | 39.87 | ||||
| Teriflunomide | 168 | 10.07 | ||||
| Fingolimod | 74 | 4.44 | ||||
| Natalizumab | 105 | 6.29 | ||||
| Ocrelizumab | 77 | 4.62 | ||||
| Cladribine | 14 | 0.84 | ||||
| Alemtuzumab | 10 | 0.6 | ||||
| Mitoxantrone | 6 | 0.36 | ||||
| Others | 38 | 2.28 |
AMS, multiple sclerosis; SD, standard deviation; IQR, interquartile range; RRMS, relapsing-remitting multiple sclerosis; PPMS, primary progressive multiple sclerosis; SPMS, secondary progressive multiple sclerosis; EDSS, the expanded disability status scale; DMTs, disease-modifying therapies.